Courier Capital LLC Has $8.85 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Courier Capital LLC decreased its position in Amgen Inc. (NASDAQ:AMGN) by 11.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 30,721 shares of the medical research company’s stock after selling 3,887 shares during the period. Courier Capital LLC’s holdings in Amgen were worth $8,848,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Briaud Financial Planning Inc acquired a new position in Amgen in the 3rd quarter valued at approximately $26,000. OFI Invest Asset Management bought a new stake in shares of Amgen in the 3rd quarter valued at approximately $26,000. Providence Capital Advisors LLC bought a new stake in shares of Amgen in the 3rd quarter valued at approximately $30,000. Strategic Investment Solutions Inc. IL bought a new stake in shares of Amgen in the 1st quarter valued at approximately $28,000. Finally, Carmel Capital Partners LLC grew its stake in shares of Amgen by 296.6% in the 3rd quarter. Carmel Capital Partners LLC now owns 115 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 86 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

AMGN has been the topic of several analyst reports. Royal Bank of Canada upped their price objective on Amgen from $303.00 to $329.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. BMO Capital Markets upgraded Amgen from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $286.00 to $326.00 in a research note on Tuesday, December 19th. Morgan Stanley decreased their price target on Amgen from $281.00 to $278.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 7th. Leerink Partnrs lowered Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 7th. Finally, Truist Financial restated a “buy” rating and set a $320.00 price target on shares of Amgen in a research report on Wednesday, November 29th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $295.30.

Amgen Price Performance

AMGN stock opened at $286.30 on Thursday. The stock has a 50-day moving average price of $290.44 and a two-hundred day moving average price of $280.66. The stock has a market cap of $153.43 billion, a PE ratio of 22.92, a price-to-earnings-growth ratio of 2.63 and a beta of 0.58. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14. Amgen Inc. has a 1 year low of $211.71 and a 1 year high of $329.72.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The firm had revenue of $8.20 billion for the quarter, compared to the consensus estimate of $8.13 billion. During the same quarter in the previous year, the business earned $4.09 earnings per share. The business’s revenue was up 19.8% compared to the same quarter last year. Equities analysts forecast that Amgen Inc. will post 19.48 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a $2.25 dividend. This represents a $9.00 annualized dividend and a dividend yield of 3.14%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is currently 72.06%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.